(Sharecast News) - AstraZeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, failing to show a statistically significant benefit against placebo on the composite measure of cardiovascular mortality and recurrent cardiovascular clinical events up to 140...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE